Current antigen-encapsulated multifunctional nanovaccines for oncotherapy suffer from limited antigen loading efficiency, low yield, tedious manufacture, and systemic toxicity. Here, an antigen-directed strategy for the fabrication of multifunctional nanovaccine with ultrahigh antigen loading efficiency in a facile way for tumor photothermal-immunotherapy is shown. As a proof of concept, a model antigen ovalbumin (OVA) is used as a natural carrier to load a representative theranostic agent indocyanine green (ICG). Mixing OVA and ICG in aqueous solution gives the simplest multifunctional nanovaccine so far. The nanovaccine owns antigen loading efficiency of 80.8%, high yield of >90%, intense near-infrared absorption and fluorescence, excellent reproducibility, good aqueous solubility and stability, and favorable biocompatibility. These merits not only guarantee sensitive labeling/tracking and efficient stimulation of dendritic cells, but also reliable imaging-guided photothermal-immunotherapy of tumors and tumor prevention. The proposed strategy provides a facile and robust method for large-scale and reproducible fabrication of multifunctional nanovaccines with ultrahigh antigen loading efficiency for tumor therapy.

Versatile bioinspired strategies are urgently needed to fabricate high‐performance nanoprobes for biomedical application. Herein, a novel bioinspired technology of mimicking drug–substrate interaction is reported for the fabrication of high‐performance nanoprobes. As a proof of concept, a multifunctional bovine serum albumin (BSA)‐MnO2 nanoparticle‐based nanoplatform is strategically engineered via mimicking the disinfection process of KMnO4 in an extremely facile way. The prepared BSA‐MnO2 nanoparticles possess sub‐10 nm and uniform size, excellent colloidal stability, and impressive T1 relaxivity of 7.9 mm−1 s−1. The proposed nanoprobe could not only be employed as a high‐performance magnetic resonance imaging (MRI) agent for tumor and renal imaging but can also provide a platform for integrating therapeutic strategies toward tumors. The universal strategy could also be easily extended to the fabrication of other nanoprobes for MR imaging in vivo using other bioactive proteins including ovalbumin and transferrin. This work will open a new way for the development of biomaterials in biomedicine applications.

Spectral computed tomography (CT) imaging as a novel imaging technique shows promising prospects in the accurate diagnosis of various diseases. However, clinically iodinated contrast agents suffer from poor signal-to-noise ratio, and emerging heavy-metal-based CT contrast agents arouse great biosafety concern. Herein, we show the fabrication of rhenium sulfide (ReS2) nanoparticles, a clinic radiotherapy sensitizer, as a biosafe spectral CT contrast agent for the gastrointestinal tract imaging and tumor theranostics in vivo by teaching old drugs new tricks. The ReS2 nanoparticles were fabricated in a one-pot facile method at room temperature, and exhibited sub-10 nm size, favorable monodispersity, admirable aqueous solubility, and strong X-ray attenuation capability. More importantly, the proposed nanoparticles possess an outstanding spectral CT imaging ability and undoubted biosafety as a clinic therapeutic agent. Besides, the ReS2 nanoparticles possess appealing photothermal performance due to their intense near-infrared absorption. The proposed nano-agent not only guarantees obvious contrast enhancement in gastrointestinal tract spectral CT imaging in vivo, but also allows effective CT imaging-guided tumor photothermal therapy. The proposed “teaching old drugs new tricks” strategy shortens the time and cuts the cost required for clinical application of nano-agents based on existing clinical toxicology testing and trial results, and lays down a low-cost, time-saving, and energy-saving method for the development of multifunctional nano-agents toward clinical applications.

Hemorrhage transformation (HT) is a frequent but maybe fatal complication following the acute ischemic stroke due to the severe damage of blood brain barrier (BBB). Quantitative BBB permeability imaging is...

Persistent luminescence material (PLM)‐based photodynamic therapy (PDT) has shown tremendous promise in tumor elimination via avoiding continuous external light illumination. In addition, the tumor‐associated antigens produced by PDT can trigger systemic antitumor immune responses, but only exhibit a limited immunotherapy effect. Herein, a persistent luminescence immune hydrogel is developed via a “turning solid into gel” strategy by introducing a PLM and an immunoadjuvant (R837) into an alginate‐Ca2+ hydrogel for rechargeable photodynamic‐immunotherapy of tumors, for the first time. The designed PLM‐R837‐ALG hydrogel exhibits the intact persistent luminescence of the PLM, 100% of utilization efficiency of the hydrophobic precursors, good biocompatibility and syringeability, and can be easily injected into tumors to serve as an internal light source for efficiently activating photosensitizers to induce a sustained PDT effect. Moreover, the loaded R837 can significantly amplify the immunogenicity of tumor‐associated antigens originating from PL sensitized PDT, thereby leading to a powerful immune response to suppress tumors in vivo. The proposed PL‐based photodynamic‐immunotherapy provides a novel combined tumor treatment paradigm.